Drugs / M4344
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04149145 | May 2023 → May 2024 | ovarian carcinoma | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 1 | NCT02278250 | Jan 2015 → Jun 2021 | cancer | EMD Serono Research & Development Institute, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04655183 | Dec 2020 → Sep 2023 | breast cancer | EMD Serono Research & Development Institute, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M4344 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02278250 ↗ |
| Known as | gartisertib | “A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.” PMID 38287179 ↗ Jan 2024 |
| Known as | VX-803 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650286 ↗ |
| Action | Inhibit | “oral inhibitor of ataxia telangiectasia and Rad3-related protein (ATR)” PMID 38287179 ↗ Jan 2024 |
| Modality | Small molecule | — CHEMBL4650286 ↗ |
| Route | Oral | “Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW)” NCT02278250 ↗ |
| Target | ATR | “inhibitor of ataxia telangiectasia and Rad3-related protein (ATR)” PMID 38287179 ↗ Jan 2024 |